21 CFR 211.130
Packaging and labeling operations.
- Inspections citing it: 349
- Of those classified, ended OAI: 28%
- Last cited: FY2026
Inspections Citing It by Fiscal Year
Sites in and outside the US, FY2017 to Oct 20, 2026.
Paragraphs Cited
As FDA posts them, all years.
- 211.130
- 142 · Procedures are written, and followed
- 211.130(e)
- 65 · Packaging line inspection before use
- 211.130(c)
- 56 · Lot or control number assigned
- 211.130(d)
- 33 · Examination of packaging and labeling
- 211.130(a)
- 29 · Prevention of cross contamination, mix-ups
- 211.130(b)
- 24 · Unlabeled filled containers controls
Regulation Text
eCFR, as of Nov 6, 2026There shall be written procedures designed to assure that correct labels, labeling, and packaging materials are used for drug products; such written procedures shall be followed. These procedures shall incorporate the following features:
(a) Prevention of mixups and cross-contamination by physical or spatial separation from operations on other drug products.
(b) Identification and handling of filled drug product containers that are set aside and held in unlabeled condition for future labeling operations to preclude mislabeling of individual containers, lots, or portions of lots. Identification need not be applied to each individual container but shall be sufficient to determine name, strength, quantity of contents, and lot or control number of each container.
(c) Identification of the drug product with a lot or control number that permits determination of the history of the manufacture and control of the batch.
(d) Examination of packaging and labeling materials for suitability and correctness before packaging operations, and documentation of such examination in the batch production record.
(e) Inspection of the packaging and labeling facilities immediately before use to assure that all drug products have been removed from previous operations. Inspection shall also be made to assure that packaging and labeling materials not suitable for subsequent operations have been removed. Results of inspection shall be documented in the batch production records.
Recently Cited Sites
Newest inspections citing this section; each opens the site- My CHS Rx, Inc.United States · Jun 5, 2026
- SnugZ USA, Inc.United States · May 1, 2026
- Regen Suppliers LLCUnited States · Dec 16, 2025
- Bello Bio LLCUnited States · Dec 16, 2025
- United Laboratories Manufacturing, LLCUnited States · Aug 15, 2025
- RemedyRePack Inc.United States · Apr 14, 2025
- Genzyme CorporationUnited States · Feb 14, 2025
- INDUCTION THERAPIES LLCUnited States · Oct 18, 2024
- Haw Par Healthcare LimitedSingapore · Sep 27, 2024
- Chara Biologics, Inc.United States · Aug 16, 2024
- Main Oxy NY, IncUnited States · Aug 5, 2024
- Revlon Group Holdings, LLCUnited States · Jan 12, 2024
Counts are inspections with posted citations that cite any paragraph of the section, once per inspection, from FDA's Data Dashboard. OAI share is over inspections FDA finally classified. Text from eCFR, the official online CFR. FDA Data Dashboard and eCFR